Repare Therapeutics Inc. (RPTX) News

Repare Therapeutics Inc. (RPTX): $3.36

0.10 (+3.07%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add RPTX to Watchlist
Sign Up

Filter RPTX News Items

RPTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest RPTX News From Around the Web

Below are the latest news stories about REPARE THERAPEUTICS INC that investors may wish to consider to help them evaluate RPTX as an investment opportunity.

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why

Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.

Yahoo | November 20, 2023

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

CAMBRIDGE, Mass. & MONTREAL, November 15, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company’s Polθ inhibitor, RP-3467.

Yahoo | November 15, 2023

Repare Therapeutics Inc. (NASDAQ:RPTX) most popular amongst private equity firms who own 33% of the shares, institutions hold 28%

Key Insights The considerable ownership by private equity firms in Repare Therapeutics indicates that they collectively...

Yahoo | November 12, 2023

These Biotech Stocks Could Double Your Money, According To Analysts

The biotech industry has been in the limelight since the COVID-19 pandemic, with public and private sectors pouring in funds to bolster innovation and the development of relevant drugs. Approximately 63% of public biotech firms reported revenue growth in 2021. Emerging biotech companies, which have annual revenue below $500 million, recorded a median 40% annual revenue growth rate, outpacing industry giants, which reported a lower 35% average annual revenue growth rate. While the pandemic-relate

Yahoo | November 9, 2023

Repare Therapeutics Inc (RPTX) Reports Q3 2023 Financial Results Amid Pipeline Progress

Initial Positive Data from MYTHIC Trial and Preclinical Program Updates

Yahoo | November 9, 2023

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

CAMBRIDGE, Mass. & MONTREAL, November 09, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Yahoo | November 9, 2023

Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast

CAMBRIDGE, Mass. & MONTREAL, November 07, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, a newly designated Polθ inhibitor, on Wednesday, November 15, 2023 at 8:00 a.m. Eastern Time.

Yahoo | November 7, 2023

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass. & MONTREAL, November 06, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows:

Yahoo | November 6, 2023

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

CAMBRIDGE, Mass. & MONTREAL, October 13, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor. The data are being presented in a plenary session titled, "New Drugs on the Horizon" at the AACR-NCI-EORTC International Conference on Molecular

Yahoo | October 13, 2023

Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround

Repare Therapeutics Inc. (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | October 11, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!